MX2018013662A - Sistema de entrega de farmacos para la entrega de agentes antivirales. - Google Patents

Sistema de entrega de farmacos para la entrega de agentes antivirales.

Info

Publication number
MX2018013662A
MX2018013662A MX2018013662A MX2018013662A MX2018013662A MX 2018013662 A MX2018013662 A MX 2018013662A MX 2018013662 A MX2018013662 A MX 2018013662A MX 2018013662 A MX2018013662 A MX 2018013662A MX 2018013662 A MX2018013662 A MX 2018013662A
Authority
MX
Mexico
Prior art keywords
delivery
antiviral agents
drug delivery
delivery system
drug
Prior art date
Application number
MX2018013662A
Other languages
English (en)
Inventor
Elizabeth BARRETT Stephanie
E Gindy Marian
Li Li
S Teller Ryan
P Forster Seth
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2018013662A publication Critical patent/MX2018013662A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

Esta invención se refiere a novedosos sistemas de entrega de fármaco de implante para entrega de larga duración de fármacos antivirales. Estas composiciones son útiles para el tratamiento o prevención de infección de virus de inmunodeficiencia humana (HIV).
MX2018013662A 2016-05-12 2017-05-08 Sistema de entrega de farmacos para la entrega de agentes antivirales. MX2018013662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335319P 2016-05-12 2016-05-12
PCT/US2017/031493 WO2017196697A1 (en) 2016-05-12 2017-05-08 Drug delivery system for the delivery of antiviral agents

Publications (1)

Publication Number Publication Date
MX2018013662A true MX2018013662A (es) 2019-03-01

Family

ID=60266868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013662A MX2018013662A (es) 2016-05-12 2017-05-08 Sistema de entrega de farmacos para la entrega de agentes antivirales.

Country Status (11)

Country Link
US (1) US11400186B2 (es)
EP (1) EP3454868A4 (es)
JP (1) JP6934019B2 (es)
KR (1) KR102272235B1 (es)
CN (2) CN109069526A (es)
AU (1) AU2017263253B2 (es)
BR (1) BR112018072883B1 (es)
CA (1) CA3023364A1 (es)
MX (1) MX2018013662A (es)
RU (1) RU2755130C2 (es)
WO (1) WO2017196697A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US11419817B2 (en) 2017-04-10 2022-08-23 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
CA3125991A1 (en) 2019-01-25 2020-07-30 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
CA3150272A1 (en) * 2019-08-13 2021-02-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统
WO2023192499A1 (en) * 2022-03-30 2023-10-05 Primefour Therapeutics, Inc. Nucleosides for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430703D0 (en) * 1984-12-05 1985-01-16 Lrc Products Drug release devices
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5601835A (en) 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US5114719A (en) 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5883144A (en) * 1994-09-19 1999-03-16 Sentinel Products Corp. Silane-grafted materials for solid and foam applications
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
WO2003094888A1 (en) * 2002-05-07 2003-11-20 Control Delivery Systems, Inc. Processes for forming a drug delivery device
CN1741792A (zh) 2003-01-24 2006-03-01 控制递送系统有限公司 经眼部递送肾上腺素能剂的持续释放系统和方法
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
EP1638536A2 (en) * 2003-05-30 2006-03-29 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
TWI434676B (zh) * 2004-03-19 2014-04-21 Merck Sharp & Dohme 可用ｘ射線看出之藥物遞送裝置
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US8993542B2 (en) * 2008-01-25 2015-03-31 Chimerix Inc. Methods of treating viral infections
WO2009126293A2 (en) 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
CA2729139C (en) * 2008-06-25 2016-07-26 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
WO2010072844A1 (en) * 2008-12-24 2010-07-01 Tibotec Pharmaceuticals Implantable devices for treating hiv
LT2547332T (lt) * 2010-03-16 2018-12-10 Titan Pharmaceuticals, Inc. Heterogeninės implantuojamos priemonės, skirtos vaisto pristatymui
US9901563B2 (en) 2013-03-11 2018-02-27 Delmar Pharmaceuticals, Inc. Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
US9441007B2 (en) * 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN105555281A (zh) * 2013-02-05 2016-05-04 人口委员会股份有限公司 用于递送抗菌组合物的独特结合的阴道环
WO2015086489A1 (en) * 2013-12-11 2015-06-18 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
WO2016149561A1 (en) * 2015-03-17 2016-09-22 Oak Crest Institute Of Science Subdermal implants for the sustained delivery of water-soluble drugs
US20190388336A1 (en) 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
WO2018057408A1 (en) 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
US11419817B2 (en) 2017-04-10 2022-08-23 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents

Also Published As

Publication number Publication date
CN115624564A (zh) 2023-01-20
CN109069526A (zh) 2018-12-21
RU2755130C2 (ru) 2021-09-13
AU2017263253B2 (en) 2022-04-14
RU2018141823A (ru) 2020-06-15
AU2017263253A1 (en) 2018-10-25
JP6934019B2 (ja) 2021-09-08
CA3023364A1 (en) 2017-11-16
US11400186B2 (en) 2022-08-02
US20190388590A1 (en) 2019-12-26
BR112018072883B1 (pt) 2023-01-17
EP3454868A1 (en) 2019-03-20
RU2018141823A3 (es) 2020-09-10
BR112018072883A2 (pt) 2019-03-06
WO2017196697A1 (en) 2017-11-16
KR102272235B1 (ko) 2021-07-01
BR112018072883A8 (pt) 2023-01-10
JP2019514992A (ja) 2019-06-06
EP3454868A4 (en) 2019-12-18
KR20190005931A (ko) 2019-01-16

Similar Documents

Publication Publication Date Title
MX2018013662A (es) Sistema de entrega de farmacos para la entrega de agentes antivirales.
MY201791A (en) Stabilized soluble pre-fusion rsv f polypeptides
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
PH12018500259A1 (en) Muscarinic agonists
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
MD4754C1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
PH12015501156A1 (en) Pharmaceutical compositions
PH12015502735B1 (en) Stabilized soluble pre-fusion rsv f polypeptides
EA029856B9 (ru) Циклические динуклеотиды в качестве модуляторов стимулятора генов интерферона (sting)
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
CR20220053A (es) Sistema de administración de medicamentos para la administración de agentes antivíricos
MX2021006992A (es) Análogos de nucleósidos de ciclobutilo como antivirales.
BR112017000543A2 (pt) agentes para o tratamento de doenças infecciosas retrovirais